Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0000950170-25-053434 0001733085 XXXXXXXX LIVE 10 Common Stock, par value $0.0001 per share 04/23/2025 false 0001350653 02081G102 Alphatec Holdings, Inc. 1950 Camino Vida Roble Carlsbad CA 92008 Jeffrey Wade, c/o LS PD, LLC 212-547-2914 1700 Broadway 35th Floor New York NY 10019 0001733085 N L-5 Healthcare Partners, LLC WC N DE 0 7201158 0 7201158 7201158 N 4.96 OO Percentage of class in row (13) represented by amount in row (11) is based on a denominator consisting of 144,149,232 shares of Common Stock outstanding as of February 19, 2025 as reported in the Issuer's Form 10-K filed on February 26, 2025, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer. Y Paul Segal OO N X1 0 7201158 0 7201158 7201158 N 4.96 IN Amounts shown in row 8 and row 10 represent 7,201,158 shares of Common Stock held by L-5 Healthcare Partners, LLC. Percentage of class in row (13) represented by amount in row (11) is based on a denominator consisting of 144,149,232 shares of Common Stock outstanding as of February 19, 2025 as reported in the Issuer's Form 10-K filed on February 26, 2025, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer. Common Stock, par value $0.0001 per share Alphatec Holdings, Inc. 1950 Camino Vida Roble Carlsbad CA 92008 Item 3 of the Schedule 13D is hereby supplemented by adding the following at the end thereof: On April 22, 2025, L-5 entered into an agreement in principle to reduce the exercise price of the Warrant from $2.17 per share to $0.01 per share, in connection with the settlement of L-5's pending motion for attorneys' fees and expenses as part of the previously disclosed litigation between the Issuer and L-5. Item 5 of this Schedule 13D is hereby amended and restated in its entirety as follows: The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. The aggregate percentage of Common Stock reported owned by each person named herein is based upon 144,149,232 shares of Common Stock outstanding as of February 19, 2025, which is the total number of shares of Common Stock outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on February 26, 2025, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer. L-5 directly holds 7,201,158 shares of Common Stock (which includes 6,067,998 shares of Common Stock and 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer) reported in this Schedule 13D. As a result of his relationship with L-5, Paul Segal may be deemed the beneficial owner of all such shares of Common Stock. Mr. Segal, however, disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein. The information set forth in Item (5)(a) of this Schedule 13D is incorporated by reference in its entirety into this Item 5(b). The transactions effected by the Reporting Persons during the past 60 days are set forth on Exhibit 1 attached hereto. Not applicable. On April 23, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock. Schedule of Transactions for Item 5(c) of Amendment No. 10. L-5 Healthcare Partners, LLC /s/ Paul Segal Paul Segal, President 04/23/2025 Paul Segal /s/ Paul Segal Paul Segal 04/23/2025